Bell Potter maintains a buy rating on MedAdvisor (ASX:MDR) and has a 12-month price target of $0.64. The buy rating is maintained by Bell Potter following another strong quarter of topline growth in the US, Australia and New Zealand, while gross margins also improved. Q4 revenue was up 32% on the previous corresponding period with full-year revenue up 25%, hence the buy rating is maintained.
- Forums
- ASX - By Stock
- MDR
- Ann: Q4 FY24 MDR Quarterly Update
MDR
medadvisor limited
Add to My Watchlist
1.27%
!
7.8¢

Ann: Q4 FY24 MDR Quarterly Update, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
7.8¢ |
Change
-0.001(1.27%) |
Mkt cap ! $48.73M |
Open | High | Low | Value | Volume |
7.6¢ | 7.8¢ | 7.5¢ | $68.98K | 890.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 240645 | 7.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.0¢ | 27812 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 13161 | 0.076 |
6 | 260645 | 0.075 |
1 | 60000 | 0.074 |
3 | 350000 | 0.073 |
1 | 78550 | 0.072 |
Price($) | Vol. | No. |
---|---|---|
0.077 | 1800 | 1 |
0.078 | 58411 | 1 |
0.080 | 27812 | 1 |
0.082 | 70000 | 1 |
0.083 | 100000 | 1 |
Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
Featured News
MDR (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
SPONSORED BY The Market Online